Kiniksa Pharmaceuticals International, plc (KNSA) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "KNSA"
      ],
      "issuer_cik": "0001730430",
      "owner_cik": "0001741533",
      "accession_number": "0001741533-26-000012",
      "form_type": "4",
      "filing_date": "2026-11-03",
      "period_of_report": "2026-10-30",
      "issuer_name": "Kiniksa Pharmaceuticals International, plc",
      "issuer_trading_symbol": "KNSA",
      "owner_name": "Paolini John F.",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "CHIEF MEDICAL OFFICER",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Class A Ordinary Share",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-30",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 16056,
      "transaction_price_per_share": 92.85,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 89664,
      "transaction_value": 1490799.5999999999,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 29, 2026."
        },
        {
          "id": "F3",
          "description": "This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.36 and $93.35. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."
        }
      ]
    },
    {
      "tickers": [
        "KNSA"
      ],
      "issuer_cik": "0001730430",
      "owner_cik": "0001857177",
      "accession_number": "0001857177-26-000010",
      "form_type": "4",
      "filing_date": "2026-11-03",
      "period_of_report": "2026-10-30",
      "issuer_name": "Kiniksa Pharmaceuticals International, plc",
      "issuer_trading_symbol": "KNSA",
      "owner_name": "Moat Ross",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "CHIEF OPERATING OFFICER",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Class A Ordinary Share",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-30",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 3672,
      "transaction_price_per_share": 96.03,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 14629,
      "transaction_value": 352622.16000000003,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 29, 2026."
        },
        {
          "id": "F6",
          "description": "This transaction was executed in multiple trades through a broker-dealer at prices ranging from $95.485 to $96.405. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.